I’m not surprised they’re reticent!
Look up Collins paper in Nature a few weeks ago – brilliant stats assessment of IP-Mass Spec to measure amyloid in PET scans and CSF samples
And it’s a very accuratealternative to CSF sampling
I do wonder if it’s commercially viable thought (I don’t know enough about IP-MS)
<<<AD Risk Confirmation>>